Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper/Cass Almendral (212) 838-1444 Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006
Delcath Systems to Present at the Maxim Group Growth Conference
| Source: Delcath Systems, Inc.
NEW YORK, NY--(Marketwire - October 2, 2008) - Delcath Systems, Inc. (NASDAQ : DCTH ), a
leading developer of regional therapy for cancer, announced today that its
management will present at the Maxim Group Growth Conference in New York
City on Tuesday, October 7, 2008. The conference will be held at the Grand
Hyatt New York Hotel. The Maxim Group Growth Conference will feature
interactive presentations from over 80 companies, as well as one-on-one
meetings with executives from the Healthcare, Technology,
Shipping/Transportation and Emerging Growth Sectors. Attendees will
include securities analysts, fund managers and institutional investors.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The Company's
intellectual property portfolio consists of twenty-eight patents on a
worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
About Maxim Group
Maxim Group is a full-service investment banking, securities and investment
management firm headquartered in New York. The Firm provides an array of
financial services including: investment banking, equity research, private
wealth management, structured products, and global institutional equity,
fixed-income and derivative sales & trading to a diverse range of corporate
clients, institutional investors and high net worth individuals. For
additional information, please visit http://www.maximgrp.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.